Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MANISH JAIN

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1417075581
CMS profile
109337
Location
CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$206,089.12

262 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 4 of 6; records 151–200 of 262 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MANISH JAIN

NPI 1417075581 · CMS profile ID 109337

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 6; records 151–200 of 262 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1417075581?year=2024&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MANISH JAIN, NPI 1417075581, CMS profile ID 109337. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 262 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417075581?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MANISH JAIN, NPI 1417075581, CMS profile ID 109337. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 262 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417075581?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MANISH JAIN, NPI 1417075581, CMS profile ID 109337, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 6; records 151–200 of 262 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1417075581?year=2024&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

262 matching records · $206,089.12 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 262 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 262.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $124.3605/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103983130 CMS
ABBVIE INC. $31.5205/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103983132 CMS
ABBVIE INC. $457.4305/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104190056 CMS
ABBVIE INC. $605.3005/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104190058 CMS
ABBVIE INC. $462.7705/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104190060 CMS
Amgen Inc. $330.7505/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111607957 CMS
Novartis Pharmaceuticals Corporation $3.0005/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087059906 CMS
Novartis Pharmaceuticals Corporation $18.7405/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087059910 CMS
ABBVIE INC. $49.4905/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103983128 CMS
ABBVIE INC. $463.6805/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104190050 CMS
ABBVIE INC. $419.6605/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104190052 CMS
ABBVIE INC. $709.5405/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104190054 CMS
Actelion Pharmaceuticals US, Inc. $29.0705/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078885507 CMS
Amgen Inc. $3,300.0005/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111607953 CMS
GlaxoSmithKline, LLC. $19.4605/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116561950 CMS
ABBVIE INC. $698.1805/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104190048 CMS
Amgen Inc. $101.7305/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111607951 CMS
Amgen Inc. $3,300.0005/01/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111607939 CMS
Amgen Inc. $400.0005/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117286263 CMS
UCB, Inc. $20.9305/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143020045 CMS
AstraZeneca Pharmaceuticals LP $21.6404/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105699646 CMS
ABBVIE INC. $23.8604/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103983120 CMS
ABBVIE INC. $62.0304/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103983122 CMS
ABBVIE INC. $57.2704/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103983124 CMS
ABBVIE INC. $23.8604/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103983126 CMS
Amgen Inc. $271.3504/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111607941 CMS
Lilly USA, LLC $9.6904/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135140508 CMS
Lilly USA, LLC $1.9404/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135140510 CMS
Amgen Inc. $30.8004/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111607933 CMS
Amgen Inc. $23.8904/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111607937 CMS
GENZYME CORPORATION $21.2304/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139787377 CMS
Janssen Biotech, Inc. $16.2404/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078578475 CMS
Janssen Biotech, Inc. $2,475.0004/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078581111 CMS
ABBVIE INC. $24.6404/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103983118 CMS
Novartis Pharmaceuticals Corporation $15.9904/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087059904 CMS
Novartis Pharmaceuticals Corporation $3.1904/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087059908 CMS
Janssen Biotech, Inc. $685.1304/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078576335 CMS
Janssen Biotech, Inc. $92.4504/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078581983 CMS
Janssen Biotech, Inc. $14.7304/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078575828 CMS
Lilly USA, LLC $22.1004/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135103305 CMS
ABBVIE INC. $118.2804/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103983116 CMS
ABBVIE INC. $601.8804/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104190046 CMS
Amgen Inc. $11.0804/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111607915 CMS
UCB, Inc. $14.5904/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143020043 CMS
Novartis Pharmaceuticals Corporation $2.4804/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087059900 CMS
Novartis Pharmaceuticals Corporation $24.0104/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087059902 CMS
ABBVIE INC. $4,550.0004/03/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103156356 CMS
Alexion Pharmaceuticals, Inc. $32.8004/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1094032756 CMS
Janssen Biotech, Inc. $2,475.0003/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078578560 CMS
Janssen Biotech, Inc. $532.6503/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078579481 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $452,629.13 585
PY2020 $261,093.45 344
PY2021 $218,009.88 380
PY2022 $232,778.36 361
PY2023 $362,282.07 485
PY2024 $206,089.12 262
PY2025 $151,778.34 209

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $6,294,424.35 217
PY2024 Recipient $81,964.76 5
PY2024 Principal investigator $6,890,002.37 327
PY2023 Principal investigator $5,216,246.96 447
PY2022 Principal investigator $4,167,588.47 992
PY2021 Principal investigator $10,218,382.27 105
PY2020 Recipient $2,400.00 1
PY2020 Principal investigator $1,737,256.74 58
PY2019 Recipient $37,429.00 2
PY2019 Principal investigator $113,567.82 39

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

217 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $636.18 12/29/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228811657
Principal investigator 1 PFIZER INC. $800.15 12/29/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228811743
Principal investigator 1 PFIZER INC. $262.77 12/29/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228811749
Principal investigator 1 PFIZER INC. $20,790.00 12/25/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228815494
Principal investigator 1 Amgen Inc. $23,500.00 12/24/2025 Non-covered Recipient Entity
GREAT LAKES CLINICAL TRIALS LLC
A Phase 3, Multicenter, Double-blind, Randomized Controlled Study Evaluating the Efficacy and Safety of Pegloticase Administered by Subcutaneous Injection Compared With Pegloticase Administered by Intravenous Injection, Both Administered Concurrently With Methotrexate Weekly, in Participants With Uncontrolled Gout No dispute reported 06/30/2026 1246641936
Principal investigator 1 Seqirus USA Inc $1,064.00 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297742
Principal investigator 1 Seqirus USA Inc $1,064.00 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297744
Principal investigator 1 Seqirus USA Inc $1,064.00 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297746
Principal investigator 1 Seqirus USA Inc $1,064.00 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297748
Principal investigator 1 Seqirus USA Inc $1,064.00 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297750
Principal investigator 1 Seqirus USA Inc $788.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297754
Principal investigator 1 Seqirus USA Inc $400.40 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297764
Principal investigator 1 Seqirus USA Inc $400.40 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297766
Principal investigator 1 Seqirus USA Inc $400.40 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297768
Principal investigator 1 Seqirus USA Inc $400.40 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297770
Principal investigator 1 Seqirus USA Inc $400.40 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297818
Principal investigator 1 Seqirus USA Inc $788.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297820
Principal investigator 1 Seqirus USA Inc $1,064.00 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297824
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297828
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297834
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297836
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297838
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297840
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297842
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297844
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297846
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297848
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297850
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297852
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297854
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297856
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297858
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297860
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297862
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297864
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297866
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297868
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297870
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297872
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297874
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297876
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297878
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297880
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297882
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297884
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297886
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297888
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297890
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297892
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297894
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297896
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297898
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297900
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297902
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297904
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297906
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297908
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297910
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297912
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297914
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297916
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297918
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297920
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297922
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297924
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297926
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297928
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297930
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297932
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297934
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297936
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297938
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297940
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297942
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297944
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297946
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297948
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297950
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297952
Principal investigator 1 Seqirus USA Inc $3,119.20 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297954
Principal investigator 1 Seqirus USA Inc $1,064.00 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297956
Principal investigator 1 Seqirus USA Inc $1,064.00 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297958
Principal investigator 1 Seqirus USA Inc $1,064.00 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297960
Principal investigator 1 Seqirus USA Inc $1,064.00 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297962
Principal investigator 1 Seqirus USA Inc $1,064.00 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297964
Principal investigator 1 Seqirus USA Inc $1,064.00 12/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297966
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,000.00 12/12/2025 Non-covered Recipient Entity
GREAT LAKES CLINICAL TRAILS
A Phase I Openlabel Randomized ActiveControlled Study in Adults to Characterize the Safety and Immunogenicity of AZD9838 Vaccine ARTEMIS C No dispute reported 06/30/2026 1185543630
Principal investigator 1 PFIZER INC. $2,668.47 12/12/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228815532
Principal investigator 1 PFIZER INC. $1,541.79 12/09/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228815592
Principal investigator 1 AstraZeneca Pharmaceuticals LP $66,632.80 12/03/2025 Non-covered Recipient Entity
GREAT LAKES CLINICAL TRAILS
A Phase I/II, Double-blinded, Randomized, Placebo-Controlled, Dose Selection Study in Adults to Assess the Safety and Immunogenicity of AZD4117 and AZD5315 Vaccines PANDA No dispute reported 06/30/2026 1185543622
Principal investigator 1 PFIZER INC. $5,119.04 11/26/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228713376
Principal investigator 1 PFIZER INC. $19,477.00 11/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228713966
Principal investigator 1 AstraZeneca UK Limited $164,340.00 11/05/2025 Non-covered Recipient Entity
QUEST DIAGNOSTICS UNIVERSITY OF MIAMI
A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 Co administered with a GLP 1 Receptor Agonist in Participants with Type 2 Diabetes and Overweight or Obesity No dispute reported 06/30/2026 1185543620
Principal investigator 1 PFIZER INC. $29,552.56 10/31/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228825084
Principal investigator 1 Seqirus USA Inc $3,846.60 10/31/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250810755
Principal investigator 1 Seqirus USA Inc $1,057.05 10/31/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250810760
Principal investigator 1 Seqirus USA Inc $2,000.00 10/27/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297826
Principal investigator 1 Seqirus USA Inc $4,925.00 10/27/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297830
Principal investigator 1 Seqirus USA Inc $11,000.00 10/27/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297832
Principal investigator 1 PFIZER INC. $87,297.67 10/25/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228825401
Principal investigator 1 ARGENX US, INC. $3,617.00 10/22/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150600
Principal investigator 1 ARGENX US, INC. $2,178.00 10/22/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150604
Principal investigator 1 ARGENX US, INC. $13,750.00 10/22/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150608
Principal investigator 1 ARGENX US, INC. $2,500.00 10/15/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150595
Principal investigator 1 ARGENX US, INC. $2,000.00 10/15/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150613
Principal investigator 1 AstraZeneca UK Limited $8,978.34 10/08/2025 Non-covered Recipient Entity
GREAT LAKES CLINICAL TRAILS
A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 Co administered with a GLP 1 Receptor Agonist in Participants with Type 2 Diabetes and Overweight or Obesity No dispute reported 06/30/2026 1185543612
Principal investigator 1 PFIZER INC. $4,044.60 10/08/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228818526
Principal investigator 1 Eli Lilly and Company $2,450.00 09/29/2025 Non-covered Recipient Entity
GREAT LAKES CLINICAL TRIALS
A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187882520
Principal investigator 1 AstraZeneca Pharmaceuticals LP $213,371.20 09/24/2025 Non-covered Recipient Entity
FLOURISH RESEARCH CHICAGO ANDERSONVILLE
A Phase I/II, Double-blinded, Randomized, Placebo-Controlled, Dose Selection Study in Adults to Assess the Safety and Immunogenicity of AZD4117 and AZD5315 Vaccines PANDA No dispute reported 06/30/2026 1185543614
Principal investigator 1 PFIZER INC. $21,186.80 09/24/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228837277
Principal investigator 1 PFIZER INC. $31,481.81 09/10/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228837270
Principal investigator 1 Seqirus USA Inc $111.30 09/10/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297814
Principal investigator 1 Seqirus USA Inc $177.19 09/10/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297816
Principal investigator 1 Seqirus USA Inc $789.00 09/10/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297822
Principal investigator 1 ARGENX US, INC. $668.50 09/03/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150566
Principal investigator 1 ARGENX US, INC. $103.50 09/03/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150572
Principal investigator 1 ARGENX US, INC. $6.65 09/03/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150577
Principal investigator 1 ARGENX US, INC. $35.80 09/03/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150582
Principal investigator 1 ARGENX US, INC. $75.20 09/03/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150586
Principal investigator 1 ARGENX US, INC. $159.00 09/03/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150590
Principal investigator 1 PFIZER INC. $4,044.60 09/03/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228837204
Principal investigator 1 PFIZER INC. $51,741.20 08/28/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228841919
Principal investigator 1 Seqirus USA Inc $2,000.00 08/13/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185297806
Principal investigator 1 Seqirus USA Inc $1,500.00 08/13/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185297808
Principal investigator 1 Seqirus USA Inc $1,600.00 08/13/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185297810
Principal investigator 1 PFIZER INC. $2,073.60 08/08/2025 Non-covered Recipient Entity
Flourish Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228713788
Principal investigator 1 Amgen Inc. $525.88 07/28/2025 Non-covered Recipient Entity
GREAT LAKES CLINICAL TRIALS LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246641927
Principal investigator 1 Eli Lilly and Company $1,200.00 07/28/2025 Non-covered Recipient Entity
INTERSPOND LLC
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187883578
Principal investigator 1 PFIZER INC. $23,955.40 07/25/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228848664
Principal investigator 1 Seqirus USA Inc $1,250.00 07/18/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185297812
Principal investigator 1 PFIZER INC. $54,481.00 07/16/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228848659
Principal investigator 1 PFIZER INC. $1,377.14 07/08/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228713784
Principal investigator 1 PFIZER INC. $533.91 07/08/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228713786
Principal investigator 1 PFIZER INC. $455.47 07/08/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228713968
Principal investigator 1 PFIZER INC. $533.91 07/08/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228713970
Principal investigator 1 PFIZER INC. $28,448.00 06/27/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228850962
Principal investigator 1 PFIZER INC. $69,328.40 06/14/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228851023
Principal investigator 1 PFIZER INC. $1,200.00 06/14/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228851035
Principal investigator 1 PFIZER INC. $2,101.17 05/21/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228855111
Principal investigator 1 PFIZER INC. $8,448.30 05/14/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228855141
Principal investigator 1 PFIZER INC. $5,118.84 05/07/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228855151
Principal investigator 1 PFIZER INC. $3,620.00 05/06/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228855146
Principal investigator 1 PFIZER INC. $2,400.38 05/02/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228855108
Principal investigator 1 AstraZeneca Pharmaceuticals LP $18,401.00 04/25/2025 Non-covered Recipient Entity
AVICENNA DM CLINICAL RESEARCH
A Phase I Openlabel Randomized ActiveControlled Study in Adults to Characterize the Safety and Immunogenicity of AZD9838 Vaccine ARTEMIS C No dispute reported 06/30/2026 1185543618
Principal investigator 1 PFIZER INC. $5,538.40 04/25/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228854578
Principal investigator 1 PFIZER INC. $339,210.00 04/24/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228854501
Principal investigator 1 PFIZER INC. $159.04 04/17/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228860478
Principal investigator 1 Eli Lilly and Company $3.90 04/15/2025 Non-covered Recipient Entity
GREAT LAKES CLINICAL TRIALS
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187882242
Principal investigator 1 PFIZER INC. $2,559.42 04/11/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228860488
Principal investigator 1 Seqirus USA Inc $538.00 04/09/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185297774
Principal investigator 1 Seqirus USA Inc $538.00 04/09/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185297778
Principal investigator 1 Seqirus USA Inc $538.00 04/09/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185297780
Principal investigator 1 Seqirus USA Inc $538.00 04/09/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185297782
Principal investigator 1 Seqirus USA Inc $538.00 04/09/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185297784
Principal investigator 1 Seqirus USA Inc $538.00 04/09/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185297786
Principal investigator 1 Seqirus USA Inc $538.00 04/09/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185297790
Principal investigator 1 Seqirus USA Inc $1,186.00 04/09/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298034
Principal investigator 1 Seqirus USA Inc $538.00 04/09/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298036
Principal investigator 1 Seqirus USA Inc $538.00 04/09/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298040
Principal investigator 1 Seqirus USA Inc $538.00 04/09/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298042
Principal investigator 1 Seqirus USA Inc $538.00 04/09/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298044
Principal investigator 1 Seqirus USA Inc $538.00 04/09/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298046
Principal investigator 1 Seqirus USA Inc $538.00 04/09/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298048
Principal investigator 1 Seqirus USA Inc $538.00 04/09/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298050
Principal investigator 1 Seqirus USA Inc $538.00 04/09/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298052
Principal investigator 1 Seqirus USA Inc $538.00 04/09/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298054
Principal investigator 1 Seqirus USA Inc $538.00 04/09/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298056
Principal investigator 1 Seqirus USA Inc $538.00 04/09/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298058
Principal investigator 1 Seqirus USA Inc $538.00 04/09/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298060
Principal investigator 1 Seqirus USA Inc $538.00 04/09/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298062
Principal investigator 1 Seqirus USA Inc $538.00 04/09/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298064
Principal investigator 1 Seqirus USA Inc $538.00 04/09/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298066
Principal investigator 1 Seqirus USA Inc $538.00 04/09/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298068
Principal investigator 1 Seqirus USA Inc $538.00 04/09/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298070
Principal investigator 1 Eli Lilly and Company $16,400.00 04/07/2025 Non-covered Recipient Entity
FLOURISH RESEARCH ACQUISITION LLC
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187883712
Principal investigator 1 PFIZER INC. $73,399.00 03/27/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228861681
Principal investigator 1 Shionogi Inc $3,800.00 03/19/2025 Non-covered Recipient Entity
GREAT LAKES CLINICAL TRIALS LL
A Phase 2, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Assess the Safety and Efficacy of S-309309 in Obese Adults No dispute reported 06/30/2026 1250717545
Principal investigator 1 Shionogi Inc $1,500.00 03/19/2025 Non-covered Recipient Entity
GREAT LAKES CLINICAL TRIALS LL
A Phase 2, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Assess the Safety and Efficacy of S-309309 in Obese Adults No dispute reported 06/30/2026 1250717550
Principal investigator 1 Shionogi Inc $1,500.00 03/19/2025 Non-covered Recipient Entity
GREAT LAKES CLINICAL TRIALS LL
A Phase 2, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Assess the Safety and Efficacy of S-309309 in Obese Adults No dispute reported 06/30/2026 1250717565
Principal investigator 1 PFIZER INC. $29,166.20 03/14/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228861749
Principal investigator 1 Eli Lilly and Company $73.86 03/12/2025 Non-covered Recipient Entity
FLOURISH RESEARCH ACQUISITION LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187882592
Principal investigator 1 PFIZER INC. $41,320.50 03/12/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228861660
Principal investigator 1 PFIZER INC. $1,706.28 03/12/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228861701
Principal investigator 1 Shionogi Inc $500.00 03/12/2025 Non-covered Recipient Entity
GREAT LAKES CLINICAL TRIALS LL
A Phase 2, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Assess the Safety and Efficacy of S-309309 in Obese Adults No dispute reported 06/30/2026 1250717541
Principal investigator 1 Eli Lilly and Company $794.04 03/10/2025 Non-covered Recipient Entity
GREAT LAKES CLINICAL TRIALS
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187881888
Principal investigator 1 ModernaTX, Inc. $2,246.00 03/05/2025 Non-covered Recipient Entity
GREAT LAKES CLINICAL TRIALS LLC
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252968001
Principal investigator 1 ModernaTX, Inc. $625.00 03/05/2025 Non-covered Recipient Entity
GREAT LAKES CLINICAL TRIALS LLC
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252968003
Principal investigator 1 ModernaTX, Inc. $1,000.00 03/05/2025 Non-covered Recipient Entity
GREAT LAKES CLINICAL TRIALS LLC
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252968005
Principal investigator 1 PFIZER INC. $4,265.70 03/05/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228861696
Principal investigator 1 AstraZeneca Pharmaceuticals LP $16,900.00 03/03/2025 Non-covered Recipient Entity
FLOURISH RESEARCH CHICAGO ANDERSONVILLE
A Phase 3 Randomized Open label Study to Assess the Immunogenicity and Safety of IVX A12 when Co-administered with a licensed influenza vaccine No dispute reported 06/30/2026 1185543626
Principal investigator 1 PFIZER INC. $2,559.42 02/26/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228836587
Principal investigator 1 Eli Lilly and Company $16,161.48 02/25/2025 Non-covered Recipient Entity
GREAT LAKES CLINICAL TRIALS
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187882816
Principal investigator 1 PFIZER INC. $126.30 02/21/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228815280
Principal investigator 1 ABBVIE INC. $7,500.00 02/20/2025 Non-covered Recipient Entity
INTERSPOND LLC
M19-944 - A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 1202453156
Principal investigator 1 PFIZER INC. $7,678.26 02/19/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228837260
Principal investigator 1 Eli Lilly and Company $1,088.18 02/17/2025 Non-covered Recipient Entity
GREAT LAKES CLINICAL TRIALS
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187881882
Principal investigator 1 PFIZER INC. $47,497.80 02/14/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228836591
Principal investigator 1 PFIZER INC. $5,247.96 02/12/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228836232
Principal investigator 1 Eli Lilly and Company $8,335.33 01/31/2025 Non-covered Recipient Entity
GREAT LAKES CLINICAL TRIALS
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187882818
Principal investigator 1 Eli Lilly and Company $3,616.53 01/30/2025 Non-covered Recipient Entity
GREAT LAKES CLINICAL TRIALS
PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY No dispute reported 06/30/2026 1187881788
Principal investigator 1 AstraZeneca Pharmaceuticals LP $45,176.00 01/29/2025 Non-covered Recipient Entity
FLOURISH RESEARCH CHICAGO ANDERSONVILLE
A Phase I Openlabel Randomized ActiveControlled Study in Adults to Characterize the Safety and Immunogenicity of AZD9838 Vaccine ARTEMIS C No dispute reported 06/30/2026 1185543628
Principal investigator 1 Eli Lilly and Company $98,488.21 01/28/2025 Non-covered Recipient Entity
FLOURISH RESEARCH ACQUISITION LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187880447
Principal investigator 1 Eli Lilly and Company $2,230.57 01/27/2025 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187882826
Principal investigator 1 PFIZER INC. $5,154.80 01/25/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228863142
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,436.31 01/21/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials - West Wilson Avenue
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease-modifying Anti-rheumatic Drugs No dispute reported 06/30/2026 1235997061
Principal investigator 1 Eli Lilly and Company $22,112.00 01/21/2025 Non-covered Recipient Entity
GREAT LAKES CLINICAL TRIALS
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187880041
Principal investigator 1 Eli Lilly and Company $147,157.30 01/17/2025 Non-covered Recipient Entity
GREAT LAKES CLINICAL TRIALS
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187882814
Principal investigator 1 AstraZeneca Pharmaceuticals LP $15,608.00 01/15/2025 Non-covered Recipient Entity
FLOURISH RESEARCH CHICAGO ANDERSONVILLE
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185543624
Principal investigator 1 PFIZER INC. $4,056.50 01/15/2025 Non-covered Recipient Entity
Great Lakes Clinical Trials LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228863163
Principal investigator 1 Eli Lilly and Company $1,890.34 01/09/2025 Non-covered Recipient Entity
GREAT LAKES CLINICAL TRIALS
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187881884
Principal investigator 1 Eli Lilly and Company $17,154.61 01/08/2025 Non-covered Recipient Entity
GREAT LAKES CLINICAL TRIALS
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187879795
Principal investigator 1 Eli Lilly and Company $173,511.00 01/07/2025 Non-covered Recipient Entity
GREAT LAKES CLINICAL TRIALS
PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY No dispute reported 06/30/2026 1187880391
Principal investigator 1 Eli Lilly and Company $314,231.00 01/07/2025 Non-covered Recipient Entity
GREAT LAKES CLINICAL TRIALS
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187881880
Principal investigator 1 Eli Lilly and Company $900,848.26 01/07/2025 Non-covered Recipient Entity
FLOURISH RESEARCH ACQUISITION LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187881892
Principal investigator 1 Eli Lilly and Company $302,707.19 01/07/2025 Non-covered Recipient Entity
GREAT LAKES CLINICAL TRIALS
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187882822
Principal investigator 1 AstraZeneca UK Limited $340,681.00 01/03/2025 Non-covered Recipient Entity
FLOURISH RESEARCH CHICAGO ANDERSONVILLE
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 1185543616
Principal investigator 1 Amgen Inc. $1,993,198.69 01/02/2025 Non-covered Recipient Entity
GREAT LAKES CLINICAL TRIALS LLC
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants No dispute reported 06/30/2026 1246641947